<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0168365913004975</prism:url><dc:identifier>doi:10.1016/j.jconrel.2013.08.028</dc:identifier><eid>1-s2.0-S0168365913004975</eid><prism:doi>10.1016/j.jconrel.2013.08.028</prism:doi><pii>S0168-3659(13)00497-5</pii><dc:title>Uptake and transport of B12-conjugated nanoparticles in airway epithelium </dc:title><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01683659</prism:issn><prism:volume>172</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:startingPage>374</prism:startingPage><prism:endingPage>381</prism:endingPage><prism:pageRange>374-381</prism:pageRange><prism:number>1</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2013-11-28</prism:coverDate><prism:coverDisplayDate>28 November 2013</prism:coverDisplayDate><prism:copyright>Copyright © 2013 Published by Elsevier B.V.</prism:copyright><prism:publisher>Published by Elsevier B.V.</prism:publisher><dc:creator>Fowler, Robyn</dc:creator><dc:creator>Vllasaliu, Driton</dc:creator><dc:creator>Falcone, Franco H.</dc:creator><dc:creator>Garnett, Martin</dc:creator><dc:creator>Smith, Bryan</dc:creator><dc:creator>Horsley, Helen</dc:creator><dc:creator>Alexander, Cameron</dc:creator><dc:creator>Stolnik, Snow</dc:creator><dc:description>AbstractNon-invasive delivery of biotherapeutics, as an attractive alternative to injections, could potentially be achieved through the mucosal surfaces, utilizing nanoscale therapeutic carriers. However, nanoparticles do not readily cross the mucosal barriers, with the epithelium presenting a major barrier to their translocation. The transcytotic pathway of vitamin B12 has previously been shown to ‘ferry’ B12-decorated nanoparticles across intestinal epithelial (Caco-2) cells. However, such studies have not been reported for the airway epithelium. Furthermore, the presence in the airways of the cell machinery responsible for transepithelial trafficking of B12 is not widely reported. Using a combination of molecular biology and immunostaining techniques, our work demonstrates that the bronchial cell line, Calu-3, expresses the B12-intrinsic factor receptor, the transcobalamin II receptor and the transcobalamin II carrier protein. Importantly, the work showed that sub-200nm model nanoparticles chemically conjugated to B12 were internalised and transported across the Calu-3 cell layers, with B12 conjugation not only enhancing cell uptake and transepithelial transport, but also influencing intracellular trafficking. Our work therefore demonstrates that the B12 endocytotic apparatus is not only present in this airway model, but also transports ligand-conjugated nanoparticles across polarised epithelial cells, indicating potential for B12-mediated delivery of nanoscale carriers of biotherapeutics across the airways.</dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName>Biotechnology and Biological Sciences Research Council</openaccessSponsorName><openaccessSponsorType>FundingBody</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by/3.0/</openaccessUserLicense><dcterms:subject>Vitamin B12</dcterms:subject><dcterms:subject>Airway epithelium</dcterms:subject><dcterms:subject>Cubilin</dcterms:subject><dcterms:subject>Calu-3 cells</dcterms:subject><dcterms:subject>Epithelial nanoparticle transport</dcterms:subject><link rel="self" href="http://api.elsevier.com/content/article/pii/S0168365913004975"/><link rel="scidir" href="http://www.sciencedirect.com/science/article/pii/S0168365913004975"/></coredata><objects><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="6559783">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1731" height="1223" size="159772">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1652" height="1146" size="159426">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1213" height="4055" size="948220">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1727" height="1375" size="266203">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1681" height="3344" size="949733">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1037" height="886" size="170104">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="391" height="276" size="19367">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="373" height="259" size="19035">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="274" height="916" size="72021">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="390" height="311" size="29313">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="754" size="74232">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="234" height="200" size="28265">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="155" size="3773">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="152" size="3855">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="49" height="164" size="4372">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="206" height="164" size="5075">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="82" height="163" size="6054">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="192" height="164" size="9669">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913004975-fx1.sml?httpAccept=%2A%2F%2A</object></objects><scopus-id>84884647191</scopus-id><scopus-eid>2-s2.0-84884647191</scopus-eid><pubmed-id>24008152</pubmed-id><link rel="abstract" href="http://api.elsevier.com/content/abstract/scopus_id/84884647191"/><originalText><xocs:doc xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://be-prod3a/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271103</xocs:cid><xocs:ssids><xocs:ssid type="alllist">291210</xocs:ssid><xocs:ssid type="subj">291681</xocs:ssid><xocs:ssid type="subj">291789</xocs:ssid><xocs:ssid type="content">31</xocs:ssid><xocs:ssid type="oa">90</xocs:ssid></xocs:ssids><xocs:srctitle>Journal of Controlled Release</xocs:srctitle><xocs:normalized-srctitle>JOURNALCONTROLLEDRELEASE</xocs:normalized-srctitle><xocs:orig-load-date yyyymmdd="20130902">2013-09-02</xocs:orig-load-date><xocs:available-online-date yyyymmdd="20130902">2013-09-02</xocs:available-online-date><xocs:ew-transaction-id>2014-09-02T08:48:08</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0168365913004975</xocs:eid><xocs:pii-formatted>S0168-3659(13)00497-5</xocs:pii-formatted><xocs:pii-unformatted>S0168365913004975</xocs:pii-unformatted><xocs:doi>10.1016/j.jconrel.2013.08.028</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.3</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0168365913X00185</xocs:hub-eid><xocs:timestamp yyyymmdd="20150514">2015-05-14T05:17:02.743021-04:00</xocs:timestamp><xocs:dco>0</xocs:dco><xocs:tomb>0</xocs:tomb><xocs:date-search-begin>20131128</xocs:date-search-begin><xocs:year-nav>2013</xocs:year-nav><xocs:indexeddate epoch="1378080000">2013-09-02T00:00:00Z</xocs:indexeddate><xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantsponsor primabst ref specialabst</xocs:articleinfo><xocs:issns><xocs:issn-primary-formatted>0168-3659</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>01683659</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>BBSRC</xocs:funding-body-id><xocs:crossmark is-crossmark="1">true</xocs:crossmark><xocs:vol-first>172</xocs:vol-first><xocs:volume-list><xocs:volume>172</xocs:volume></xocs:volume-list><xocs:iss-first>1</xocs:iss-first><xocs:issue-list><xocs:issue>1</xocs:issue></xocs:issue-list><xocs:vol-iss-suppl-text>Volume 172, Issue 1</xocs:vol-iss-suppl-text><xocs:sort-order>42</xocs:sort-order><xocs:first-fp>374</xocs:first-fp><xocs:last-lp>381</xocs:last-lp><xocs:pages><xocs:first-page>374</xocs:first-page><xocs:last-page>381</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20131128</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>28 November 2013</xocs:cover-date-text><xocs:cover-date-start>2013-11-28</xocs:cover-date-start><xocs:cover-date-year>2013</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Nanomedicine</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 Published by Elsevier B.V.</xocs:copyright-line><xocs:normalized-article-title>UPTAKETRANSPORTB12CONJUGATEDNANOPARTICLESINAIRWAYEPITHELIUM</xocs:normalized-article-title><xocs:normalized-first-auth-surname>FOWLER</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>R</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of the α-ω-aminohexylcarbamate derivative of cyanocobalamin</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title>Characterisation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title>Cell culture</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>mRNA expression of cubilin and TCII receptor in Calu-3 cells</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5.1</xocs:item-toc-label><xocs:item-toc-section-title>mRNA isolation and cDNA synthesis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5.2</xocs:item-toc-label><xocs:item-toc-section-title>Primer design</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5.3</xocs:item-toc-label><xocs:item-toc-section-title>Polymerase chain reaction (PCR)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5.4</xocs:item-toc-label><xocs:item-toc-section-title>DNA agarose gel electrophoresis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title>Immunostaining for cubilin, transcobalamin II receptor and transcobalamin II protein</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>Cellular uptake and transport studies of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>Immunostaining for clathrin and caveolin-1</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.9</xocs:item-toc-label><xocs:item-toc-section-title>Clathrin and caveolae inhibition studies</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.10</xocs:item-toc-label><xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title>Cubilin and TCII receptor expression in Calu-3 cells</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1.1</xocs:item-toc-label><xocs:item-toc-section-title>mRNA expression</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>Characterisation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title>Cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.4</xocs:item-toc-label><xocs:item-toc-section-title>Cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles: confocal microscopy</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.5</xocs:item-toc-label><xocs:item-toc-section-title>Immunostaining for clathrin and caveolin-1</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.6</xocs:item-toc-label><xocs:item-toc-section-title>Epithelial trafficking of soluble B<ce:inf loc="post">12</ce:inf></xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.7</xocs:item-toc-label><xocs:item-toc-section-title>Airway epithelial cell trafficking of B<ce:inf loc="post">12</ce:inf> conjugated nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4</xocs:item-toc-label><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>5</xocs:item-toc-label><xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:appendices"><xocs:item-toc-label>Appendix A</xocs:item-toc-label><xocs:item-toc-section-title>Supplementary</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>THANOU</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>117</xocs:ref-first-fp><xocs:ref-last-lp>126</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>VLLASALIU</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>151</xocs:ref-first-fp><xocs:ref-last-lp>160</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>SALAMA</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>15</xocs:ref-first-fp><xocs:ref-last-lp>28</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>VLLASALIU</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>579</xocs:ref-first-fp><xocs:ref-last-lp>585</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>RUSSELLJONES</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>459</xocs:ref-first-fp><xocs:ref-last-lp>465</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>TUMA</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>871</xocs:ref-first-fp><xocs:ref-last-lp>932</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>RUSSELLJONES</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>247</xocs:ref-first-fp><xocs:ref-last-lp>255</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>VLLASALIU</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>479</xocs:ref-first-fp><xocs:ref-last-lp>486</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>RUSSELLJONES</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>ORALDELIVERYTHERAPEUTICPROTEINSPEPTIDESBYVITAMINB12UPTAKESYSTEM</xocs:ref-normalized-srctitle></xocs:ref-info><xocs:ref-info refid="or0015"/><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>CHALASANI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>141</xocs:ref-first-fp><xocs:ref-last-lp>150</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>RUSSELLJONES</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>113</xocs:ref-first-fp><xocs:ref-last-lp>123</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>DIX</xocs:ref-normalized-surname><xocs:ref-pub-year>1990</xocs:ref-pub-year><xocs:ref-first-fp>1272</xocs:ref-first-fp><xocs:ref-last-lp>1279</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>RAMANUJAM</xocs:ref-normalized-surname><xocs:ref-pub-year>1991</xocs:ref-pub-year><xocs:ref-first-fp>G416</xocs:ref-first-fp><xocs:ref-last-lp>G422</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>SCHOHN</xocs:ref-normalized-surname><xocs:ref-pub-year>1991</xocs:ref-pub-year><xocs:ref-first-fp>427</xocs:ref-first-fp><xocs:ref-last-lp>430</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>GUEANT</xocs:ref-normalized-surname><xocs:ref-pub-year>1992</xocs:ref-pub-year><xocs:ref-first-fp>229</xocs:ref-first-fp><xocs:ref-last-lp>232</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>CHALASANI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>421</xocs:ref-first-fp><xocs:ref-last-lp>429</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>FOWLER</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>VORTHERMS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>9792</xocs:ref-first-fp><xocs:ref-last-lp>9794</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="or0020"/><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>MORADI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>3025</xocs:ref-first-fp><xocs:ref-last-lp>3033</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>SAMBROOK</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>MOLECULARCLONINGALABORATORYMANUAL</xocs:ref-normalized-srctitle></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>REJMAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>159</xocs:ref-first-fp><xocs:ref-last-lp>169</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>265</xocs:ref-first-fp><xocs:ref-last-lp>270</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>176</xocs:ref-first-fp><xocs:ref-last-lp>181</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>BRADBURY</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>L659</xocs:ref-first-fp><xocs:ref-last-lp>L668</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>MOTLEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>909</xocs:ref-first-fp><xocs:ref-last-lp>918</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>LAKADAMYALI</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>997</xocs:ref-first-fp><xocs:ref-last-lp>1009</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>ORLANDI</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>905</xocs:ref-first-fp><xocs:ref-last-lp>915</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>SCHNITZER</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>1217</xocs:ref-first-fp><xocs:ref-last-lp>1232</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>PONS</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>135</xocs:ref-first-fp><xocs:ref-last-lp>148</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>BOSE</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>20920</xocs:ref-first-fp><xocs:ref-last-lp>20928</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>BOSE</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>3538</xocs:ref-first-fp><xocs:ref-last-lp>3543</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>SAHALI</xocs:ref-normalized-surname><xocs:ref-pub-year>1992</xocs:ref-pub-year><xocs:ref-first-fp>33</xocs:ref-first-fp><xocs:ref-last-lp>44</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>HAMMAD</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>12003</xocs:ref-first-fp><xocs:ref-last-lp>12008</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>SEETHARAM</xocs:ref-normalized-surname><xocs:ref-pub-year>1981</xocs:ref-pub-year><xocs:ref-first-fp>3785</xocs:ref-first-fp><xocs:ref-last-lp>3790</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>GLIEMANN</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>951</xocs:ref-first-fp><xocs:ref-last-lp>964</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>WILLNOW</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>306</xocs:ref-first-fp><xocs:ref-last-lp>315</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>PEDERSEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>706</xocs:ref-first-fp><xocs:ref-last-lp>720</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>MOESTRUP</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>8612</xocs:ref-first-fp><xocs:ref-last-lp>8617</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>CHRISTENSEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>256</xocs:ref-first-fp><xocs:ref-last-lp>266</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>ZIELINSKADAWIDZIAK</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>423</xocs:ref-first-fp><xocs:ref-last-lp>429</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>SARTI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>13</xocs:ref-first-fp><xocs:ref-last-lp>19</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>TRONDE</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>1216</xocs:ref-first-fp><xocs:ref-last-lp>1233</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>CRATER</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>1473</xocs:ref-first-fp><xocs:ref-last-lp>1483</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1482</xocs:ref-first-fp><xocs:ref-last-lp>1487</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>CU</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>173</xocs:ref-first-fp><xocs:ref-last-lp>181</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>ELBERT</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>601</xocs:ref-first-fp><xocs:ref-last-lp>608</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>DAUM</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>31</xocs:ref-first-fp><xocs:ref-last-lp>42</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>HUMANCELLCULTUREPROTOCOLS</xocs:ref-normalized-srctitle><xocs:ref-normalized-article-title>ISOLATIONCULTIVATIONAPPLICATIONHUMANALVEOLAREPITHELIALCELLS</xocs:ref-normalized-article-title></xocs:ref-info></xocs:references><xocs:refkeys><xocs:refkey3>FOWLERX2013X374</xocs:refkey3><xocs:refkey4lp>FOWLERX2013X374X381</xocs:refkey4lp><xocs:refkey4ai>FOWLERX2013X374XR</xocs:refkey4ai><xocs:refkey5>FOWLERX2013X374X381XR</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-09-04T12:23:21Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type><xocs:oa-sponsor-name>Biotechnology and Biological Sciences Research Council</xocs:oa-sponsor-name></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0168-3659(13)00497-5</xocs:pii-formatted><xocs:pii-unformatted>S0168365913004975</xocs:pii-unformatted><xocs:eid>1-s2.0-S0168365913004975</xocs:eid><xocs:doi>10.1016/j.jconrel.2013.08.028</xocs:doi><xocs:cid>271103</xocs:cid><xocs:timestamp>2014-09-02T07:06:51.493087-04:00</xocs:timestamp><xocs:cover-date-start>2013-11-28</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>BBSRC</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0168365913004975-main.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/MAIN/application/pdf/c6e7b85a7829d4a032ef74e1351957d9/main.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/MAIN/application/pdf/c6e7b85a7829d4a032ef74e1351957d9/main.pdf</xocs:ucs-locator><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>1055565</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>8</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0168365913004975-main_1.png</xocs:attachment-eid><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/PREVIEW/image/png/d8976e9199cfd3b32d0b6853659b5f6f/main_1.png</xocs:ucs-locator><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/PREVIEW/image/png/d8976e9199cfd3b32d0b6853659b5f6f/main_1.png</xocs:ucs-locator><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>61051</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-mmc1.docx</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/mmc1/MAIN/application/msword/921dd5186505ddca0eecab46b4806911/mmc1.docx</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/mmc1/MAIN/application/msword/921dd5186505ddca0eecab46b4806911/mmc1.docx</xocs:ucs-locator><xocs:file-basename>mmc1</xocs:file-basename><xocs:filename>mmc1.docx</xocs:filename><xocs:extension>docx</xocs:extension><xocs:filesize>6559783</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr5_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr5/HIGHRES/image/jpeg/58219225cfb8e037a464e97c8d8c7ebc/gr5_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr5/HIGHRES/image/jpeg/58219225cfb8e037a464e97c8d8c7ebc/gr5_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>159772</xocs:filesize><xocs:pixel-height>1223</xocs:pixel-height><xocs:pixel-width>1731</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr4_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr4/HIGHRES/image/jpeg/43589457afa0e6a9d5743cbcfb3e110d/gr4_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr4/HIGHRES/image/jpeg/43589457afa0e6a9d5743cbcfb3e110d/gr4_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>159426</xocs:filesize><xocs:pixel-height>1146</xocs:pixel-height><xocs:pixel-width>1652</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr3_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr3/HIGHRES/image/jpeg/f31789b19d5e63fccac173be7d8c0160/gr3_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr3/HIGHRES/image/jpeg/f31789b19d5e63fccac173be7d8c0160/gr3_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>948220</xocs:filesize><xocs:pixel-height>4055</xocs:pixel-height><xocs:pixel-width>1213</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr2/HIGHRES/image/jpeg/13c0f2f7eb46a455d1a04a1409469ec8/gr2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr2/HIGHRES/image/jpeg/13c0f2f7eb46a455d1a04a1409469ec8/gr2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>266203</xocs:filesize><xocs:pixel-height>1375</xocs:pixel-height><xocs:pixel-width>1727</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr1/HIGHRES/image/jpeg/c8636cca1c97ab62067d63f551e9fe88/gr1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr1/HIGHRES/image/jpeg/c8636cca1c97ab62067d63f551e9fe88/gr1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>949733</xocs:filesize><xocs:pixel-height>3344</xocs:pixel-height><xocs:pixel-width>1681</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-fx1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/fx1/HIGHRES/image/jpeg/ea6f30cfe2fe36ab06f537f5164a3cc3/fx1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/fx1/HIGHRES/image/jpeg/ea6f30cfe2fe36ab06f537f5164a3cc3/fx1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>170104</xocs:filesize><xocs:pixel-height>886</xocs:pixel-height><xocs:pixel-width>1037</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr5.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr5/DOWNSAMPLED/image/jpeg/aa233831c8f6986dc17a52c1733fd443/gr5.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr5/DOWNSAMPLED/image/jpeg/aa233831c8f6986dc17a52c1733fd443/gr5.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>19367</xocs:filesize><xocs:pixel-height>276</xocs:pixel-height><xocs:pixel-width>391</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr4.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr4/DOWNSAMPLED/image/jpeg/5882a308fc6d9cf3a06399a65f5741b2/gr4.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr4/DOWNSAMPLED/image/jpeg/5882a308fc6d9cf3a06399a65f5741b2/gr4.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>19035</xocs:filesize><xocs:pixel-height>259</xocs:pixel-height><xocs:pixel-width>373</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr3.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr3/DOWNSAMPLED/image/jpeg/468c420b258425ff34b49f70e7a7f09c/gr3.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr3/DOWNSAMPLED/image/jpeg/468c420b258425ff34b49f70e7a7f09c/gr3.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>72021</xocs:filesize><xocs:pixel-height>916</xocs:pixel-height><xocs:pixel-width>274</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr2/DOWNSAMPLED/image/jpeg/5837ac885d5efa40213a8422abe18e07/gr2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr2/DOWNSAMPLED/image/jpeg/5837ac885d5efa40213a8422abe18e07/gr2.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>29313</xocs:filesize><xocs:pixel-height>311</xocs:pixel-height><xocs:pixel-width>390</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr1/DOWNSAMPLED/image/jpeg/46b0361b56a6169f6b27915d920748d4/gr1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr1/DOWNSAMPLED/image/jpeg/46b0361b56a6169f6b27915d920748d4/gr1.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>74232</xocs:filesize><xocs:pixel-height>754</xocs:pixel-height><xocs:pixel-width>379</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-fx1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/fx1/DOWNSAMPLED/image/jpeg/2ae49a21f4174b715e9fa038550ef1c1/fx1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/fx1/DOWNSAMPLED/image/jpeg/2ae49a21f4174b715e9fa038550ef1c1/fx1.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>28265</xocs:filesize><xocs:pixel-height>200</xocs:pixel-height><xocs:pixel-width>234</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr5.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr5/THUMBNAIL/image/gif/d7c0d0b45378db71da5874d1e0547fad/gr5.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr5/THUMBNAIL/image/gif/d7c0d0b45378db71da5874d1e0547fad/gr5.sml</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3773</xocs:filesize><xocs:pixel-height>155</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr4.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr4/THUMBNAIL/image/gif/435d44d4687530cef428d4562131f50e/gr4.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr4/THUMBNAIL/image/gif/435d44d4687530cef428d4562131f50e/gr4.sml</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3855</xocs:filesize><xocs:pixel-height>152</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr3.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr3/THUMBNAIL/image/gif/d6e673cbcf6af973859787547b6c69d0/gr3.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr3/THUMBNAIL/image/gif/d6e673cbcf6af973859787547b6c69d0/gr3.sml</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>4372</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>49</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr2/THUMBNAIL/image/gif/a2375c59a3550bbcd2e338ced655cd22/gr2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr2/THUMBNAIL/image/gif/a2375c59a3550bbcd2e338ced655cd22/gr2.sml</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5075</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>206</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-gr1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/gr1/THUMBNAIL/image/gif/523c91e519e3950b1488878379aa5cdc/gr1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/gr1/THUMBNAIL/image/gif/523c91e519e3950b1488878379aa5cdc/gr1.sml</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6054</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>82</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913004975-fx1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913004975/fx1/THUMBNAIL/image/gif/c53d8e7d6723608a3185986be05f91da/fx1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913004975/fx1/THUMBNAIL/image/gif/c53d8e7d6723608a3185986be05f91da/fx1.sml</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>9669</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>192</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc></xocs:meta><xocs:serial-item><article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>COREL</jid><aid>6857</aid><ce:pii>S0168-3659(13)00497-5</ce:pii><ce:doi>10.1016/j.jconrel.2013.08.028</ce:doi><ce:copyright type="unknown" year="2013"/><ce:copyright-line>© 2013</ce:copyright-line></item-info><ce:floats><ce:figure id="f0010"><ce:label>Fig. 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0015" view="all">Cubilin, TCII receptor and TCII protein expression in polarised Calu-3 cells on day 21 of culture. a) mRNA expression of (i) cubilin (lanes 1 &amp; 2) and (ii) TCII receptor (CD320) (lanes 3 &amp; 4). *Ctrl denotes PCR product obtained from Caco-2 cell monolayer. b) Immunostaining for cubilin (i–ii), TCII receptor (iii–iv) and TCII (v–vi). i) Red signal from Rhodamine-labelled goat, anti-rabbit IgG antibody to rabbit anti-human cubilin H-300 primary antibody. ii) Control experiment where cells were treated with Rhodamine-labelled goat, anti-rabbit IgG only (<ce:italic>i.e.</ce:italic> treatment with the primary antibody was omitted). iii) Cells immunostained for TCII receptor with rabbit, anti-human CD320 antibody and chicken, anti-rabbit Alexa Fluor 488 secondary antibody. iv) Control experiment showing cells treated with chicken, anti-rabbit Alexa Fluor 488 secondary antibody only. v) Cells immunostained for TCII with rabbit, anti-human TCII H-260 and Rhodamine-labelled goat, anti-rabbit IgG secondary antibody. vi) Control experiment in which cells were treated with Rhodamine-labelled goat, anti-rabbit IgG only. Blue<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>cell nuclei stained with Hoechst. Micrographs shown as overlay images showing both blue and red or blue and green channels.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 2</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0020" view="all">Cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles in Calu-3 layers: a) Cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles (50<ce:hsp sp="0.25"/>nm and 100<ce:hsp sp="0.25"/>nm) in the presence and absence of intrinsic factor (IF) and unmodified nanoparticles. b) Transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles (50 and 100<ce:hsp sp="0.25"/>nm) in the presence and absence of IF, and unmodified nanoparticles. c) Nanoparticle transport flux. Data represents the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 3</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0025" view="all">Expression of select endocytic components by immunohistochemistry in Calu-3 cells (as polarised layers). a) Expression of clathrin, as demonstrated by cell incubation with rabbit anti-clathrin primary antibody and goat, anti-rabbit IgG-FITC (i), and control monolayer treated with the secondary, goat, anti-rabbit IgG-FITC only (ii). b) Expression of caveolin-1, shown by treating cells with anti-human caveolin 1H-97, followed by goat, anti-rabbit IgG-Rhodamine (i), and control monolayer, incubated with goat, anti-rabbit IgG-Rhodamine only (ii). Cell nuclei were labelled with Hoechst 33342 (blue) in all cases. Immunostaining for all components was performed on day 21 of Transwell culture.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 4</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" view="all">Effect of endocytic pathway-specific inhibitors on cell uptake and transport of soluble vitamin B<ce:inf loc="post">12</ce:inf> in Calu-3 cell layers. a) Effect of chlorpromazine and filipin on cell uptake of B<ce:inf loc="post">12</ce:inf>. b) Effect of chlorpromazine and filipin on transport of B<ce:inf loc="post">12</ce:inf> across Calu-3 layers. c) Soluble vitamin B<ce:inf loc="post">12</ce:inf> transport flux. B<ce:inf loc="post">12</ce:inf> was applied in combination with IF and quantified by UVAbs (350<ce:hsp sp="0.25"/>nm). Data represents the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD.</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 5</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" view="all">Effect of endocytic pathway-specific inhibitors on cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles in Calu-3 cell layers. a) Effect of chlorpromazine and filipin on the cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles in Calu-3 layers. b) Effect of chlorpromazine and filipin on transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles across Calu-3 layers. c) Nanoparticle transport flux. Cell uptake and transport studies were conducted with B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles of 100<ce:hsp sp="0.25"/>nm diameter and in the presence of IF. Data represents the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD.</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure></ce:floats><head><ce:title id="ti0005">Uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles in airway epithelium</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Robyn</ce:given-name><ce:surname>Fowler</ce:surname><ce:cross-ref refid="af0005" id="cf0005"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0010"><ce:given-name>Driton</ce:given-name><ce:surname>Vllasaliu</ce:surname><ce:cross-ref refid="af0005" id="cf0010"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0015"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au0015"><ce:given-name>Franco H.</ce:given-name><ce:surname>Falcone</ce:surname><ce:cross-ref refid="af0010" id="cf0020"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0020"><ce:given-name>Martin</ce:given-name><ce:surname>Garnett</ce:surname><ce:cross-ref refid="af0005" id="cf0025"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0025"><ce:given-name>Bryan</ce:given-name><ce:surname>Smith</ce:surname><ce:cross-ref refid="af0015" id="cf0030"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0030"><ce:given-name>Helen</ce:given-name><ce:surname>Horsley</ce:surname><ce:cross-ref refid="af0015" id="cf0035"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0035"><ce:given-name>Cameron</ce:given-name><ce:surname>Alexander</ce:surname><ce:cross-ref refid="af0005" id="cf0040"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0040"><ce:given-name>Snow</ce:given-name><ce:surname>Stolnik</ce:surname><ce:cross-ref refid="af0005" id="cf0045"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0050"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">Snjezana.Stolnik@nottingham.ac.uk</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK</ce:textfn><sa:affiliation><sa:organization>Division of Drug Delivery and Tissue Engineering</sa:organization><sa:organization>School of Pharmacy</sa:organization><sa:organization>University of Nottingham</sa:organization><sa:city>Nottingham</sa:city><sa:postal-code>NG7 2RD</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Division of Molecular and Cellular Science, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK</ce:textfn><sa:affiliation><sa:organization>Division of Molecular and Cellular Science</sa:organization><sa:organization>School of Pharmacy</sa:organization><sa:organization>University of Nottingham</sa:organization><sa:city>Nottingham</sa:city><sa:postal-code>NG7 2RD</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">UCB Pharma, 208 Bath Road, Slough, Berkshire SL1 3WE, UK</ce:textfn><sa:affiliation><sa:organization>UCB Pharma</sa:organization><sa:address-line>208 Bath Road, Slough</sa:address-line><sa:city>Berkshire</sa:city><sa:postal-code>SL1 3WE</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Corresponding author. Tel.: +<ce:hsp sp="0.10"/>44 1158 466074; fax: +<ce:hsp sp="0.10"/>44 1159 515102.</ce:text></ce:correspondence><ce:footnote id="fn0005"><ce:label>1</ce:label><ce:note-para id="np0005" view="all">Present address: MHT Building MC3111, Lincoln School of Pharmacy, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK.</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="2" month="6" year="2013"/><ce:date-accepted day="24" month="8" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">Non-invasive delivery of biotherapeutics, as an attractive alternative to injections, could potentially be achieved through the mucosal surfaces, utilizing nanoscale therapeutic carriers. However, nanoparticles do not readily cross the mucosal barriers, with the epithelium presenting a major barrier to their translocation. The transcytotic pathway of vitamin B<ce:inf loc="post">12</ce:inf> has previously been shown to ‘ferry’ B<ce:inf loc="post">12</ce:inf>-decorated nanoparticles across intestinal epithelial (Caco-2) cells. However, such studies have not been reported for the airway epithelium. Furthermore, the presence in the airways of the cell machinery responsible for transepithelial trafficking of B<ce:inf loc="post">12</ce:inf> is not widely reported. Using a combination of molecular biology and immunostaining techniques, our work demonstrates that the bronchial cell line, Calu-3, expresses the B<ce:inf loc="post">12</ce:inf>-intrinsic factor receptor, the transcobalamin II receptor and the transcobalamin II carrier protein. Importantly, the work showed that sub-200<ce:hsp sp="0.25"/>nm model nanoparticles chemically conjugated to B<ce:inf loc="post">12</ce:inf> were internalised and transported across the Calu-3 cell layers, with B<ce:inf loc="post">12</ce:inf> conjugation not only enhancing cell uptake and transepithelial transport, but also influencing intracellular trafficking. Our work therefore demonstrates that the B<ce:inf loc="post">12</ce:inf> endocytotic apparatus is not only present in this airway model, but also transports ligand-conjugated nanoparticles across polarised epithelial cells, indicating potential for B<ce:inf loc="post">12</ce:inf>-mediated delivery of nanoscale carriers of biotherapeutics across the airways.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical" id="ab0010" view="all"><ce:section-title id="st0010">Graphical abstract</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0010" view="all">The vitamin B<ce:inf loc="post">12</ce:inf> endocytic system is present in the airways, being able to transport B<ce:inf loc="post">12</ce:inf>-functionalized nanoparticles transepithelially. B<ce:inf loc="post">12</ce:inf>-nanoparticles display enhanced apical-to-basolateral transport, and a different trafficking behaviour to soluble B<ce:inf loc="post">12</ce:inf>.<ce:display><ce:figure id="f0005"><ce:link locator="fx1" id="lk0030"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" view="all" class="keyword"><ce:section-title id="st0015">Keywords</ce:section-title><ce:keyword id="kw0030"><ce:text id="tx0010">Vitamin B<ce:inf loc="post">12</ce:inf></ce:text></ce:keyword><ce:keyword id="kw0035"><ce:text id="tx0015">Airway epithelium</ce:text></ce:keyword><ce:keyword id="kw0040"><ce:text id="tx0020">Cubilin</ce:text></ce:keyword><ce:keyword id="kw0045"><ce:text id="tx0025">Calu-3 cells</ce:text></ce:keyword><ce:keyword id="kw0050"><ce:text id="tx0030">Epithelial nanoparticle transport</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0020">Introduction</ce:section-title><ce:para id="p0005" view="all">Considering the recent emergence of biotherapeutics, developments in non-invasive delivery options for this class of medicines have been disappointing, with the parenteral method remaining the predominant administration route. Non-invasive administration <ce:italic>via</ce:italic> the mucosal surfaces (<ce:italic>e.g.</ce:italic> gut or airway epithelia) is highly desirable, but at the same time a formidable task, primarily due to the poor absorption of biomacromolecules across the mucosae. Mucosal absorption of biomolecules could potentially be improved by inducing reversible ‘opening’ of the epithelial tight junctions, creating a temporarily accessible corridor for the therapeutic to traverse the epithelial barrier <ce:cross-refs refid="bb0005 bb0010 bb0015" id="cf0055">[1–3]</ce:cross-refs>. This strategy however may be limited to relatively small biomolecules (peptides or small proteins), whilst systemic delivery of larger biotherapeutics (<ce:italic>e.g.</ce:italic> antibodies or PEGylated antibody fragments) through this approach is shown to be inefficient <ce:cross-ref refid="bb0020" id="cf0060">[4]</ce:cross-ref>. Furthermore, the longer-term implications of repeated opening of the tight junctions are currently unclear. Mucosal absorption of the therapeutic <ce:italic>via</ce:italic> transport through the epithelial cells (<ce:italic>i.e.</ce:italic> the transcellular route) would potentially overcome this problem.</ce:para><ce:para id="p0010" view="all">A number of biological transport pathways operate at mucosal surfaces, ‘shuttling’ various molecules including nutrients (<ce:italic>e.g.</ce:italic> vitamin B<ce:inf loc="post">12</ce:inf> <ce:cross-ref refid="bb0025" id="cf0065">[5]</ce:cross-ref>) and endogenous macromolecules (<ce:italic>e.g.</ce:italic> albumin and IgG <ce:cross-ref refid="bb0030" id="cf0070">[6]</ce:cross-ref>) across the epithelium. These physiological pathways could potentially be exploited for transmucosal delivery of biomolecules, delivered encapsulated within appropriately decorated nanoparticulate carriers <ce:cross-refs refid="bb0035 bb0040" id="cf0075">[7,8]</ce:cross-refs>.</ce:para><ce:para id="p0015" view="all">The present work investigated whether the vitamin B<ce:inf loc="post">12</ce:inf> (herein referred to ‘B<ce:inf loc="post">12</ce:inf>’) pathway could carry decorated nanoparticles across the airway mucosa. The B<ce:inf loc="post">12</ce:inf> transcytotic pathway has demonstrated potential for intestinal delivery of peptides and proteins <ce:cross-refs refid="bb0035 bb0045 bb0050 bb0055 bb0060" id="cf0080">[7,9–12]</ce:cross-refs> and its presence has been confirmed in intestinal cell lines, Caco-2 <ce:cross-refs refid="bb0065 bb0070" id="cf0085">[13,14]</ce:cross-refs> and HT29 <ce:cross-refs refid="bb0075 bb0080" id="cf0090">[15,16]</ce:cross-refs>. Importantly, the B<ce:inf loc="post">12</ce:inf> pathway has also been shown to transport nanoparticles across intestinal Caco-2 cells <ce:cross-refs refid="bb0055 bb0085 bb0090" id="cf0095">[11,17,18]</ce:cross-refs>. Whilst the possibility of targeting the B<ce:inf loc="post">12</ce:inf> transcytosis pathway for delivery of biotherapeutics and nanocarriers has been demonstrated in the intestinal epithelium, information on the presence and its functioning in the pulmonary system is sparse <ce:cross-ref refid="bb0095" id="cf0100">[19]</ce:cross-ref> and knowledge on the drug delivery potential of this epithelial transport route in the airway epithelium is currently not available.</ce:para><ce:para id="p0020" view="all">Here we demonstrate the expression and functioning of the B<ce:inf loc="post">12</ce:inf> transcytotic system in differentiated, polarised culture of bronchial Calu-3 cells, and extend this to probing whether this pathway can be exploited for transairway delivery of nanoparticles as model therapeutic carriers. The objective of this work stems from other published studies by our group, which showed folate receptor expression and its endocytotic activity in airway epithelial cells <ce:cross-refs refid="bb0100 bb0105" id="cf0105">[20,21]</ce:cross-refs>. Initial experiments assessed the expression of relevant pathway components: intrinsic factor (IF)-B<ce:inf loc="post">12</ce:inf> receptor (‘cubilin’), the transcobalamin II receptor (‘TCII receptor’) and transcobalamin II carrier protein (‘TCII protein’), the latter being responsible for the delivery of B<ce:inf loc="post">12</ce:inf> out of the basolateral membrane of epithelial cells <ce:italic>in vivo</ce:italic>. We further show cellular internalisation and transepithelial transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles and unravel the endocytic mechanisms involved in the trafficking of B<ce:inf loc="post">12</ce:inf>-decorated nanoparticles.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0025">Materials and methods</ce:section-title><ce:para id="p0025" view="all">Solid 1,1′-carbonyldiimidazole (CDI), anhydrous dimethyl sulfoxide, cyanocobalamin and N-hydroxy-succinimide (NHS) were purchased from Acros® (Belgium). 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC) was obtained from Calbiochem® (UK). Unless otherwise stated, all other chemicals and materials were supplied by Sigma-Aldrich® (UK) or Fisher Scientific® (UK).</ce:para><ce:section id="s0030" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0050">Preparation of the α-ω-aminohexylcarbamate derivative of cyanocobalamin</ce:section-title><ce:para id="p0035" view="all">The α-ω-aminohexylcarbamate derivative of cyanocobalamin was prepared using a method described previously <ce:cross-ref refid="bb0090" id="cf0110">[18]</ce:cross-ref>. Briefly, solid CDI (260<ce:hsp sp="0.25"/>mg, 0.32<ce:hsp sp="0.25"/>mmol) was added to cyanocobalamin (1.0<ce:hsp sp="0.25"/>g, 0.148<ce:hsp sp="0.25"/>mmol) previously dissolved in anhydrous dimethyl sulfoxide. The mixture was stirred for up to 2<ce:hsp sp="0.25"/>h at 30<ce:hsp sp="0.25"/>°C, followed by the addition of dry 1,6-hexanediamine (314<ce:hsp sp="0.25"/>mg, 0.54<ce:hsp sp="0.25"/>mmol) and stirring of the mixture at room temperature over 24<ce:hsp sp="0.25"/>h. The mixture was poured into ethyl acetate (30<ce:hsp sp="0.25"/>ml) and left to stand. Following centrifugation and decanting of the supernatant, the residue was sonicated for 5<ce:hsp sp="0.25"/>min in acetone (50<ce:hsp sp="0.25"/>ml). The resulting precipitate was filtered and the solid washed in acetone. The crude product was purified by silica column chromatography (45% v/v 2-propanol, 30% v/v n-butanol, 2% v/v ammonia and 25% v/v water) followed by lyophilisation.</ce:para></ce:section><ce:section id="s0035" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0055">Preparation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</ce:section-title><ce:para id="p0045" view="all">1<ce:hsp sp="0.25"/>ml of fluorescent carboxylate Yellow Orange (YO, fluorescence spectra equivalent to rhodamine) polystyrene nanoparticles of 50<ce:hsp sp="0.25"/>nm, and 100<ce:hsp sp="0.25"/>nm (2.69 and 2.6% w/v aqueous suspension, respectively; PolySciences Inc., Germany) were modified with the α-ω-aminohexylcarbamate B<ce:inf loc="post">12</ce:inf> derivative (10<ce:hsp sp="0.25"/>mg) by activation with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC), in the presence of N-hydroxy-succinimide (NHS). The reaction was allowed to proceed for 5<ce:hsp sp="0.25"/>h followed by incubation with glycine (100<ce:hsp sp="0.25"/>mg/ml) in 50<ce:hsp sp="0.25"/>mM carbonate buffer, pH<ce:hsp sp="0.25"/>9.5, to block residual activated carboxyl sites. The particles were then dialyzed extensively against distilled water over 24<ce:hsp sp="0.25"/>h, whilst exchanging the water at regular intervals.</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0060">Characterisation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</ce:section-title><ce:para id="p0055" view="all">Extensive characterization of the B<ce:inf loc="post">12</ce:inf> derivative and the conjugated nanoparticles (<ce:italic>e.g.</ce:italic> size and surface charge determination pre- and post-B<ce:inf loc="post">12</ce:inf> conjugation) was described in a recent publication by our group <ce:cross-ref refid="bb0090" id="cf0115">[18]</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0065">Cell culture</ce:section-title><ce:para id="p0065" view="all">Calu-3 cells (American Type Culture Collection, USA) were cultured using Eagle's Minimum Essential Medium (LGC standards, UK), supplemented with penicillin (100<ce:hsp sp="0.25"/>units/ml), streptomycin (0.1<ce:hsp sp="0.25"/>mg/ml), amphotericin (0.25<ce:hsp sp="0.25"/>μg/ml) and Foetal Bovine Serum (FBS, 10% v/v). Cells were seeded on Transwell® inserts (12<ce:hsp sp="0.25"/>mm diameter, 0.4<ce:hsp sp="0.25"/>μm pore size; Corning Life Sciences, Holland) at 10<ce:sup loc="post">5</ce:sup><ce:hsp sp="0.25"/>cells/cm<ce:sup loc="post">2</ce:sup> and cultured for 14–21<ce:hsp sp="0.25"/>days, with medium replacement every other day. Calu-3 cells were cultured using air-interfaced culture (AIC) conditions (known to promote mucus secretion), which were created on day 2 post-seeding on filter supports. Cell confluence and cell layer integrity following nanoparticle exposure were confirmed by transepithelial electrical resistance measurements (TEER) using an EVOM (World Precision Elements, USA) voltohmmeter. TEER post-nanoparticle incubation did not drop significantly (Supporting information, Fig. S1), suggesting no effect on the integrity of the cell layers.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0070">mRNA expression of cubilin and TCII receptor in Calu-3 cells</ce:section-title><ce:section id="s0055" view="all"><ce:label>2.5.1</ce:label><ce:section-title id="st0075">mRNA isolation and cDNA synthesis</ce:section-title><ce:para id="p0075" view="all">The μMACS™ (Miltenyi Biotec, UK) was used to extract mRNA and synthesise cDNA from Calu-3 cells and Caco-2 cells (used as a control) cultured on Transwell® supports for 21<ce:hsp sp="0.25"/>days. This single-step technique that captures mRNA magnetically with oligo-dT magnetic beads was conducted according to the manufacturer's recommended protocol. Note, that 50<ce:hsp sp="0.25"/>μl of sscDNA was collected per tube of which 20<ce:hsp sp="0.25"/>μl was collected and pooled for primer optimisation.</ce:para></ce:section><ce:section id="s0060" view="all"><ce:label>2.5.2</ce:label><ce:section-title id="st0080">Primer design</ce:section-title><ce:para id="p0080" view="all">The ensemble database was consulted for primer design (<ce:inter-ref xlink:href="http://www.ensembl.org" id="ir0020" xlink:type="simple">www.ensembl.org</ce:inter-ref>). PCR primers for human cubilin (HsCUBN_FOR): 5′-TCCGGCAGACATTGGGGCCT-3′ and (HsCUBN_REV): 5′-TCCGTGACCCTGCGGTGAGT-3′ were designed from human cubilin sequence, National Center for Biotechnology Information (NCBI) Reference Sequence <ce:inter-ref xlink:href="ncbi-n:NM_001081.3" id="ir0025" xlink:type="simple">NM_001081.3</ce:inter-ref>. PCR primers for human TCII receptor (CD320) (HsCD320_FOR): 5′-CACCCACCAAGTTCCAGTGCCG-3′ and (HsCD320_REV): 5′-GTTCCACAGCCGAGCTCGTCG-3′ were designed from human CD320 sequence, NCBI Reference Sequence <ce:inter-ref xlink:href="ncbi-n:NM_016579.3" id="ir0030" xlink:type="simple">NM_016579.3</ce:inter-ref>. Primers for cubilin span an exon–exon junction with an intron size of 18,192 basepairs (forward primer) and 3947 basepairs (reverse primer). The primers for CD320 include an intron with a size of 942<ce:hsp sp="0.25"/>bp. Both primer pairs were blasted against the human genome (Primer-Blast on NCBI Blast) and identified one single amplicon of the correct size in each case.</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>2.5.3</ce:label><ce:section-title id="st0085">Polymerase chain reaction (PCR)</ce:section-title><ce:para id="p0085" view="all">Standard PCR ready-to-use Master Mix (REDTaq® ReadyMix™ PCR Reaction Mix, Sigma-Aldrich, UK) was used to prepare the PCR reaction mixture. The final reaction mixture consisted of 10<ce:hsp sp="0.25"/>μl PCR Master-Mix, 1<ce:hsp sp="0.25"/>μl each of forward and reverse primers for the gene of interest (5<ce:hsp sp="0.25"/>μM each final concentration), 1<ce:hsp sp="0.25"/>μl DNA template (extracted cDNA of filter-cultured Calu-3 and Caco-2 cells) and 7<ce:hsp sp="0.25"/>μl nuclease free water (Roche, UK), making a final volume of 20<ce:hsp sp="0.25"/>μl per microtube. PCR amplification of cDNA for human cubilin was performed using the following sequential cycles: initial heating at 94<ce:hsp sp="0.25"/>°C for 5<ce:hsp sp="0.25"/>min, 94<ce:hsp sp="0.25"/>°C for 30<ce:hsp sp="0.25"/>s, annealing at 60<ce:hsp sp="0.25"/>°C for 45<ce:hsp sp="0.25"/>s, extension at 72<ce:hsp sp="0.25"/>°C for 90<ce:hsp sp="0.25"/>s, and this cycling repeated 34 times, followed by a final extension at 72<ce:hsp sp="0.25"/>°C for 5<ce:hsp sp="0.25"/>min to ensure completion of all strands. A similar PCR programme was followed for human TCII receptor but with denaturation steps at 58<ce:hsp sp="0.25"/>°C. Reactions were carried out in a PTC-200 Peltier Thermal Cycler (MJ Research, UK). The reaction mixes were incubated at 4<ce:hsp sp="0.25"/>°C prior to DNA agarose gel electrophoresis.</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>2.5.4</ce:label><ce:section-title id="st0090">DNA agarose gel electrophoresis</ce:section-title><ce:para id="p0090" view="all">The PCR products of 602<ce:hsp sp="0.25"/>bp and 343<ce:hsp sp="0.25"/>bp for cubilin and TCII receptor, respectively, were analysed by DNA Agarose gel electrophoresis. Agarose gels were prepared using a well-established protocol, developed by the group and adapted from Sambrook and Russell <ce:cross-ref refid="bb0110" id="cf0120">[22]</ce:cross-ref>. Briefly, 1% (w/v) agarose gels were prepared using analytical grade agarose (Promega, UK) in 0.5X TBE buffer (1<ce:hsp sp="0.25"/>M Tris–HCl; 1<ce:hsp sp="0.25"/>M Boric Acid; 0.05<ce:hsp sp="0.25"/>M EDTA; pH<ce:hsp sp="0.25"/>8.0) with the addition of ethidium bromide (10<ce:hsp sp="0.25"/>μg/ml). 8<ce:hsp sp="0.25"/>μl (0.8<ce:hsp sp="0.25"/>μg) of TriDye 100<ce:hsp sp="0.25"/>bp DNA Ladder was loaded per gel lane (2 lanes per gel on either side of DNA samples). The DNA samples were loaded (15–20<ce:hsp sp="0.25"/>μl per gel lane) and the gels were run in 0.5X Tris/Borate/EDTA (TBE) buffer and electrophoresis was performed using a horizontal gel apparatus (Fisher Scientific, UK) at 100–110<ce:hsp sp="0.25"/>V. DNA fragments were visualised on a UV transilluminator with Gene Genius Bio imaging software (UVP, USA).</ce:para></ce:section></ce:section><ce:section id="s0075" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0095">Immunostaining for cubilin, transcobalamin II receptor and transcobalamin II protein</ce:section-title><ce:para id="p0100" view="all">Following culture as polarised layers, Calu-3 cells were fixed using 4% w/v paraformaldehyde (in PBS) for 10<ce:hsp sp="0.25"/>min at room temperature. Cells were then washed with PBS, followed by incubation with 1% w/v BSA in PBS for 1<ce:hsp sp="0.25"/>h. The cells were then subjected to 30<ce:hsp sp="0.25"/>min incubation with rabbit, anti-human cubilin H-300 (Santa Cruz Biotechnology, Inc.), rabbit, anti-human CD320 (TCII receptor, Abcam) or rabbit transcobalamin II H-260 (Santa Cruz Biotechnology, Inc.), all diluted 1:50 with 1% w/v BSA/PBS. The cells were then washed extensively with PBS and incubated with the secondary antibodies (chicken anti-rabbit Alexa-Fluor 488 for TCII receptor, and goat, anti-rabbit IgG-rhodamine, for cubilin and TCII), diluted 1:100 (in 1% w/v BSA/PBS) for another 30<ce:hsp sp="0.25"/>min. In the control experiment cell layers were incubated with the secondary antibodies only. Following a final wash step, cell nuclei were stained with Hoechst 33342 (0.1<ce:hsp sp="0.25"/>mg/ml), the cells washed and the filter membrane excised. Cells were mounted on a slide using 1,4-diazabicyclo[2.2.2]octane (DABCO) (1% diluted in 9:1 glycerol:PBS) and covered with a glass cover slip. Confocal imaging was carried out using a Leica SP2 CLSM-Micro4 confocal microscope (Leica, Germany).</ce:para></ce:section><ce:section id="s0080" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0100">Cellular uptake and transport studies of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</ce:section-title><ce:para id="p0110" view="all">Culture medium was removed from filter-cultured Calu-3 cells (cultured using AIC conditions) and replaced with Hank's Balanced Salt Solution (HBSS), buffered with 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES, 20<ce:hsp sp="0.25"/>mM); cell layers were incubated with HBSS for 45<ce:hsp sp="0.25"/>min. Unmodified YO nanoparticles (50, 100<ce:hsp sp="0.25"/>nm) and B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles were suspended in HBSS/HEPES to achieve a final concentration of 400<ce:hsp sp="0.25"/>μg/ml. Approximately 0.115<ce:hsp sp="0.25"/>μg of recombinant human intrinsic factor (rHUIF, Autogen Bioclear Ltd) was added per 1<ce:hsp sp="0.25"/>ng of B<ce:inf loc="post">12</ce:inf> and the solution was incubated at 37<ce:hsp sp="0.25"/>°C prior to application to cells. Following a routine measurement of TEER (to assess cell layer integrity and hence their suitability for inclusion in the experiments) nanoparticle suspensions (0.5<ce:hsp sp="0.25"/>ml) were applied to the apical chamber of quadruplicate wells and the Calu-3 cultures incubated at 37<ce:hsp sp="0.25"/>°C over 3<ce:hsp sp="0.25"/>h. B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles were also applied to the cells in the absence of IF. At 30<ce:hsp sp="0.25"/>minute sampling intervals, 100<ce:hsp sp="0.25"/>μl was removed from the basolateral side and analysed for fluorescence. Sample losses were replaced with 100<ce:hsp sp="0.25"/>μl of HEPES/HBSS to maintain the basolateral volume constant. Internalised fluorescence (indicating nanoparticle uptake) was determined by cell lysis using 0.2% Triton X-100 (Fluka) (10<ce:hsp sp="0.25"/>min incubation). Cell uptake of nanoparticles was quantified by fluorescence (Dynex, microplate reader, 529<ce:hsp sp="0.25"/>nm/546<ce:hsp sp="0.25"/>nm) using calibration curves (conducted in triplicates, in the medium replicating the experimental conditions). Soluble B<ce:inf loc="post">12</ce:inf> transport studies were conducted in a similar manner to nanoparticle transport experiments, with B<ce:inf loc="post">12</ce:inf> quantified by UV (350<ce:hsp sp="0.25"/>nm, Beckman Coulter DU 800 UV spectrophotometer).</ce:para></ce:section><ce:section id="s0085" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0105">Immunostaining for clathrin and caveolin-1</ce:section-title><ce:para id="p0120" view="all">For immunostaining experiments, culture medium was removed and cells incubated with HBSS for 45<ce:hsp sp="0.25"/>min. The cell monolayers were then fixed with 4% paraformaldehyde (diluted in PBS) for 10<ce:hsp sp="0.25"/>min at room temperature. For these studies, an additional permeabilization step was conducted <ce:italic>via</ce:italic> the addition of 0.2% Triton X-100 for 10<ce:hsp sp="0.25"/>min. The cells were washed with PBS, before incubation with 1% BSA/PBS (for 1<ce:hsp sp="0.25"/>h). The primary antibody for caveolin-1 (rabbit, anti-human caveolin-1 H-97 IgG; Santa Cruz Biotechnology, Inc., USA) was diluted 1:50 with 1% BSA/PBS and incubated with the cells for 30<ce:hsp sp="0.25"/>min. For clathrin immunostaining, rabbit, anti-human clathrin IgG (Abcam®, UK) was diluted 1:200 in 1% BSA/PBS. The cells were washed 3 times with PBS and incubated with the secondary antibody (goat, anti-rabbit IgG-rhodamine and goat, anti-rabbit IgG-FITC for caveolin-1 and clathrin, respectively) diluted 1:100 (in 1% BSA/PBS) for another 30<ce:hsp sp="0.25"/>min. The control cell layers were incubated with the appropriate secondary antibody only. Following a final wash step, the cell nuclei were stained with Hoechst 33342 (0.1<ce:hsp sp="0.25"/>mg/ml), the cells washed and the filter membrane excised from the insert. Cells were mounted on a slide using 1,4-diazabicyclo[2.2.2]octane (DABCO) (1% diluted in 9:1 glycerol:PBS) and covered with a glass cover slip. Confocal imaging was carried out using a Leica SP2 CLSM-Micro4 confocal microscope.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:label>2.9</ce:label><ce:section-title id="st0110">Clathrin and caveolae inhibition studies</ce:section-title><ce:para id="p0130" view="all">Filipin (5<ce:hsp sp="0.25"/>μg/ml) and chlorpromazine (10<ce:hsp sp="0.25"/>μg/ml) were used as inhibitors of specific endocytic pathways (caveolae and clathrin, respectively). Cells were treated with the inhibitors, in HBSS/HEPES, for 1<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C prior to the addition of particles <ce:cross-ref refid="bb0115" id="cf0125">[23]</ce:cross-ref>. Unmodified and B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles (as IF composites and without IF) were applied in HBSS/HEPES (400<ce:hsp sp="0.25"/>μg/ml) containing one of the above inhibitors and incubated for 3<ce:hsp sp="0.25"/>h. Control experiments with known ligands for the clathrin- and caveolae- mediated pathways (FITC-transferrin at 100<ce:hsp sp="0.25"/>μg/ml and cholera toxin-B-subunit at 5<ce:hsp sp="0.25"/>μg/ml, respectively) were carried out as described previously <ce:cross-ref refid="bb0090" id="cf0130">[18]</ce:cross-ref>. To assess the trafficking route of soluble vitamin B<ce:inf loc="post">12</ce:inf> and compare with that of B<ce:inf loc="post">12</ce:inf>-bearing nanoparticles, vitamin B<ce:inf loc="post">12</ce:inf> (1<ce:hsp sp="0.25"/>mg/ml), in the presence of IF, was also applied in conjunction with the same inhibitors and cell uptake and transport determined <ce:italic>via</ce:italic> UV-absorbance at 350<ce:hsp sp="0.25"/>nm.</ce:para></ce:section><ce:section id="s0095" view="all"><ce:label>2.10</ce:label><ce:section-title id="st0115">Statistical analysis</ce:section-title><ce:para id="p0140" view="all">All experiments were carried out using triplicate samples and were repeated three times. One way analysis of variance (ANOVA) followed by Bonferroni post-hoc test was applied for comparison of group means of three or more groups, whilst Student's <ce:italic>t</ce:italic>-test was used for comparison of two groups. Data shown as the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD of three different experiments. p values of &lt;<ce:hsp sp="0.10"/>0.05 were considered statistically significant. *, ** and *** denote p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 and p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001, respectively, whilst ‘ns’ indicates non-significant.</ce:para></ce:section></ce:section><ce:section id="s0015" view="all"><ce:label>3</ce:label><ce:section-title id="st0030">Results</ce:section-title><ce:section id="s0100" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0120">Cubilin and TCII receptor expression in Calu-3 cells</ce:section-title><ce:section id="s0105" view="all"><ce:label>3.1.1</ce:label><ce:section-title id="st0125">mRNA expression</ce:section-title><ce:para id="p0150" view="all">PCR and gel electrophoresis analysis of differentiated Calu-3 cells (cultured on permeable supports as polarised layers), conducted to determine mRNA expression of cubilin (human CUBN gene) and the gene encoding TCII receptor (CD320), is shown in <ce:cross-ref refid="f0010" id="cf0135">Fig. 1</ce:cross-ref>a<ce:float-anchor refid="f0010"/>. The data confirm the expression of both cubilin (i) and TCII receptor (ii) (cDNA amplification products of 602 and 343<ce:hsp sp="0.25"/>bp, respectively). A secondary fragment (~<ce:hsp sp="0.10"/>260<ce:hsp sp="0.25"/>bp) with weak intensity, in addition to the band detected at 343<ce:hsp sp="0.25"/>bp (for CD320), was also detected, which possibly results from an alternatively spliced transcript variant encoding a different isoform.</ce:para><ce:para id="p0155" view="all">The expression of cubilin, TCII receptor and TCII protein, at protein level, is demonstrated by immunostaining. This is shown in <ce:cross-ref refid="f0010" id="cf0140">Fig. 1</ce:cross-ref>b. Considering the expression of cubilin, fluorescence signal was detected and appears distributed across the depth of the cell layer in the sample treated with both primary and secondary antibodies (<ce:cross-ref refid="f0010" id="cf0145">Fig. 1</ce:cross-ref>b i), implying a non-polar receptor distribution. Fluorescence was not apparent in the control experiment where treatment with the primary antibody was omitted (<ce:cross-ref refid="f0010" id="cf0150">Fig. 1</ce:cross-ref>b ii). Immunostaining for TCII receptor reveals intense staining, indicating its expression in Calu-3 cells (<ce:cross-ref refid="f0010" id="cf0155">Fig. 1</ce:cross-ref>b iii). No fluorescence was detected in the control experiment (<ce:italic>i.e.</ce:italic> treatment with the secondary antibody only, <ce:cross-ref refid="f0010" id="cf0160">Fig. 1</ce:cross-ref>b iv). Immunostaining for TCII protein, a carrier protein involved in the binding and transport of B<ce:inf loc="post">12</ce:inf> out of the enterocytes <ce:italic>in vivo</ce:italic>, indicates its presence in Calu-3 cells (<ce:cross-ref refid="f0010" id="cf0165">Fig. 1</ce:cross-ref>b v), whilst fluorescence signal was largely absent in the relevant control experiment (<ce:cross-ref refid="f0010" id="cf0170">Fig. 1</ce:cross-ref>b vi).</ce:para></ce:section></ce:section><ce:section id="s0110" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0130">Characterisation of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</ce:section-title><ce:para id="p0165" view="all">The characterisation of amino-derivatized B12 by means of nuclear magnetic resonance (NMR), mass spectrometry (MS), and high-performance liquid chromatography (HPLC), as well as characterisation of conjugated nanoparticles is shown in our recently published work, which employed the same B<ce:inf loc="post">12</ce:inf>-modified nanoparticles <ce:cross-ref refid="bb0090" id="cf0175">[18]</ce:cross-ref>. Briefly, nanoparticle size and surface charge before and after B<ce:inf loc="post">12</ce:inf> conjugation were determined by dynamic light scattering and zeta potential measurements, demonstrating a change in both parameters post-B<ce:inf loc="post">12</ce:inf> conjugation. The presence of B<ce:inf loc="post">12</ce:inf> on the surface of conjugated polystyrene nanoparticles was confirmed by fluorescence quenching, based on the fluorescence quenching ability of B<ce:inf loc="post">12</ce:inf>, which was previously demonstrated in work by our group <ce:cross-ref refid="bb0090" id="cf0180">[18]</ce:cross-ref> and others <ce:cross-refs refid="bb0120 bb0125" id="cf0185">[24,25]</ce:cross-refs>. This is shown by experiments determining the fluorescence of physical mixtures of nanoparticles and B<ce:inf loc="post">12,</ce:inf> as well as B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles before and after dialysis (performed to separate soluble B<ce:inf loc="post">12</ce:inf> from unconjugated nanoparticles). The data shown in Supporting information, Fig. S2, demonstrates that B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles displayed a lower fluorescence intensity compared to unmodified nanoparticles and that fluorescence remained unchanged following dialysis (unlike physical mixtures of soluble B<ce:inf loc="post">12</ce:inf> and nanoparticles).</ce:para></ce:section><ce:section id="s0115" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0135">Cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles</ce:section-title><ce:para id="p0175" view="all"><ce:cross-ref refid="f0015" id="cf0190">Fig. 2</ce:cross-ref>a<ce:float-anchor refid="f0015"/> provides a comparison of cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles with unmodified counterparts of the same pre-conjugation diameter. Following a three-hour incubation period, the uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles by Calu-3 cells was larger compared to unmodified nanoparticles. This trend applied to both 50<ce:hsp sp="0.25"/>nm (45<ce:hsp sp="0.25"/>μg <ce:italic>versus</ce:italic> 31<ce:hsp sp="0.25"/>μg for B<ce:inf loc="post">12</ce:inf>-conjugated and unmodified nanoparticles, respectively) and 100<ce:hsp sp="0.25"/>nm systems (15<ce:hsp sp="0.25"/>μg <ce:italic>versus</ce:italic> 8<ce:hsp sp="0.25"/>μg). Testing the effect of intrinsic factor (IF) on the cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles, <ce:cross-ref refid="f0015" id="cf0195">Fig. 2</ce:cross-ref>a also shows that the presence of IF in the system modestly promoted the uptake of B<ce:inf loc="post">12</ce:inf>-nanoparticles, with the effect being marginally larger for 50<ce:hsp sp="0.25"/>nm nanoparticles (1.25-fold increase), compared to 100<ce:hsp sp="0.25"/>nm nanoparticles (1.16-fold).</ce:para><ce:para id="p0180" view="all">Mirroring the cell uptake data, the results showing nanoparticle transport across polarised cells (<ce:cross-ref refid="f0015" id="cf0200">Fig. 2</ce:cross-ref>b and c) revealed that B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles traversed Calu-3 cell layers more efficiently than the unmodified counterparts, regardless of their size. The difference in transport between B<ce:inf loc="post">12</ce:inf>-bearing and unmodified nanoparticles of the same nominal diameter was notable: 0.240–0.292<ce:hsp sp="0.25"/>ng/s/cm<ce:sup loc="post">2</ce:sup> <ce:italic>versus</ce:italic> 0.077<ce:hsp sp="0.25"/>ng/s/cm<ce:sup loc="post">2</ce:sup> (up to 3.8-fold difference) and 0.98–1.263<ce:hsp sp="0.25"/>ng/s/cm<ce:sup loc="post">2</ce:sup> <ce:italic>versus</ce:italic> 0.047<ce:hsp sp="0.25"/>ng/s/cm<ce:sup loc="post">2</ce:sup> (up to 27-fold difference) for 50<ce:hsp sp="0.25"/>nm and 100<ce:hsp sp="0.25"/>nm nanoparticles, respectively. Transport of nanoparticles over 3<ce:hsp sp="0.25"/>h was somewhat lower in the absence of IF and the level of transport was significantly larger for 100<ce:hsp sp="0.25"/>nm, relative to 50<ce:hsp sp="0.25"/>nm nanoparticles, with or without the presence of IF in the system. Cumulative apical-to-basolateral transport of 100<ce:hsp sp="0.25"/>nm nanoparticles at the end of the three-hour exposure reached high levels of approximately 15<ce:hsp sp="0.25"/>μg — a similar level to the amount nanoparticles found intracellularly at this time point.</ce:para></ce:section><ce:section id="s0120" view="all"><ce:label>3.4</ce:label><ce:section-title id="st0140">Cell uptake of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles: confocal microscopy</ce:section-title><ce:para id="p0190" view="all">Confocal micrographs of polarised Calu-3 cells following incubation with unmodified and B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles are presented in Supporting information, Fig. S3a and b, respectively. In both conditions the micrographs clearly show the presence of nanoparticle-emitting red fluorescence signal within the cells. Imaging in sections across the depth of the cells shows the distribution of fluorescence across the vertical plane of the cell layers (depicted on the right and bottom sides of the images), indicating nanoparticle presence deep within the cells, rather than simple association with the cell membranes. It must be noted that nanoparticle fluorescence signal was more apparent for unmodified nanoparticles compared to B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles (imaged under the same confocal microscopy settings), though quantitation of nanoparticle uptake demonstrated that the latter were taken up by the cells more efficiently (Supporting information, Fig. S3a). This is probably due to the prominent fluorescence quenching capacity of B<ce:inf loc="post">12</ce:inf>, as shown in Supporting information, Fig. S2.</ce:para></ce:section><ce:section id="s0125" view="all"><ce:label>3.5</ce:label><ce:section-title id="st0145">Immunostaining for clathrin and caveolin-1</ce:section-title><ce:para id="p0200" view="all">Calu-3 expression of key proteins relevant in two specific endocytic pathways, namely clathrin (implicated in the trafficking of the soluble B<ce:inf loc="post">12</ce:inf>-IF complex) and caveolae pathways, was confirmed by immunostaining. The data shown in <ce:cross-ref refid="f0020" id="cf0205">Fig. 3</ce:cross-ref><ce:float-anchor refid="f0020"/> confirmed the expression of these proteins (clathrin and caveolin-1 in <ce:cross-ref refid="f0020" id="cf0210">Fig. 3</ce:cross-ref>a and b, respectively) in the airway model, as shown by the presence of fluorescence signal in cell samples treated with the relevant antibodies and lack of fluorescence in control samples where exposure to the secondary, fluorescently-tagged antibody was omitted. This is in agreement with previously reported findings <ce:cross-ref refid="bb0130" id="cf0215">[26]</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0130" view="all"><ce:label>3.6</ce:label><ce:section-title id="st0150">Epithelial trafficking of soluble B<ce:inf loc="post">12</ce:inf></ce:section-title><ce:para id="p0210" view="all">Studies assessing the uptake and transport route of soluble B<ce:inf loc="post">12</ce:inf> in airway epithelial cell layers were undertaken using endocytic pathway-specific inhibitors, chlorpromazine and filipin. Specific inhibition of cell uptake pathways by these agents in Calu-3 cells was examined by assessing their effect on the uptake and transport of clathrin and caveolae pathway-selective ligands, transferrin <ce:cross-refs refid="bb0135 bb0140" id="cf0220">[27,28]</ce:cross-refs> and cholera toxin B-subunit <ce:cross-refs refid="bb0145 bb0150" id="cf0225">[29,30]</ce:cross-refs>, respectively (Supplementary information, Fig. S4). Cell uptake of FITC-transferrin in the presence of chlorpromazine was inhibited by approximately 2-fold (Fig. S4a), whilst filipin induced a dramatic 21-fold decrease in the cellular internalisation of cholera toxin B-subunit (Fig. S4b).</ce:para><ce:para id="p0215" view="all">Considering the effect of endocytosis inhibitors on cell uptake and transepithelial transport of soluble B<ce:inf loc="post">12</ce:inf>, <ce:cross-ref refid="f0025" id="cf0230">Fig. 4</ce:cross-ref><ce:float-anchor refid="f0025"/> shows that both agents had an impact on cell uptake (<ce:cross-ref refid="f0025" id="cf0235">Fig. 4</ce:cross-ref>a), with filipin causing a modest reduction in cell uptake (by approximately 25%) and chlorpromazine having a markedly more prominent effect with a 95% suppression of soluble B<ce:inf loc="post">12</ce:inf> uptake. A similar observation was noted in transport studies: soluble B<ce:inf loc="post">12</ce:inf> transport across filipin-treated cells was reduced compared to untreated cells, with a notable inhibitory effect in the initial phases of the experiment (<ce:cross-ref refid="f0025" id="cf0240">Fig. 4</ce:cross-ref>b), which latter recovered. Overall transport inhibition by filipin, as determined from flux values (<ce:cross-ref refid="f0025" id="cf0245">Fig. 4</ce:cross-ref>c), amounted to 23%. Chlorpromazine on the other hand induced a high level of transport inhibition (with a reduction in flux by 94%).</ce:para></ce:section><ce:section id="s0135" view="all"><ce:label>3.7</ce:label><ce:section-title id="st0155">Airway epithelial cell trafficking of B<ce:inf loc="post">12</ce:inf> conjugated nanoparticles</ce:section-title><ce:para id="p0225" view="all">Cell uptake of 100<ce:hsp sp="0.25"/>nm B<ce:inf loc="post">12</ce:inf>-nanoparticles was affected by both chlorpromazine and filipin treatment, producing a statistically significant reduction in the extent of nanoparticle uptake (<ce:cross-ref refid="f0030" id="cf0250">Fig. 5</ce:cross-ref>a<ce:float-anchor refid="f0030"/>). Treatment with chlorpromazine induced a 3.4-fold decrease in nanoparticle internalisation (p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.002), whereas application of filipin caused a 2.1-fold reduction in the extent of uptake (p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.004). Transport data also illustrates the same phenomenon: after 3<ce:hsp sp="0.25"/>h, cumulative amounts of B<ce:inf loc="post">12</ce:inf>-nanoparticles on the basal side in untreated cells reached ~<ce:hsp sp="0.10"/>17<ce:hsp sp="0.25"/>μg, <ce:italic>versus</ce:italic> 0.9 and 0.4<ce:hsp sp="0.25"/>μg, in filipin- and chlorpromazine-treated cells, respectively (<ce:cross-ref refid="f0030" id="cf0255">Fig. 5</ce:cross-ref>b). Nanoparticle flux across the airway epithelium was reduced dramatically by 96.9% and 97.4% due to chlorpromazine and filipin treatment, respectively (<ce:cross-ref refid="f0030" id="cf0260">Fig. 5</ce:cross-ref>c). These trends therefore suggest that cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles was noticeably affected by the inhibition of either clathrin or caveolae-mediated routes in airway Calu-3 cells.</ce:para></ce:section></ce:section><ce:section id="s0020" view="all"><ce:label>4</ce:label><ce:section-title id="st0035">Discussion</ce:section-title><ce:para id="p0230" view="all">Non-invasive delivery of biotherapeutics for a systemic effect is potentially feasible with administration <ce:italic>via</ce:italic> the mucosal surfaces. However, the epithelium presents an almost impenetrable barrier to the movement of macromolecular therapeutics into the systemic circulation. Natural epithelial transport pathways involved in the absorption of nutrients (<ce:italic>e.g.</ce:italic> vitamin B<ce:inf loc="post">12</ce:inf> and folate) or regulation of immune responses (IgG/FcRn) have therefore been considered as potentially useful targets to ‘hijack’ for delivery of therapeutics and/or therapeutic carriers such as nanoparticles. However, not many known pathways are able to efficiently transport material transepithelially (<ce:italic>i.e.</ce:italic> transfer cargo across the cells, as opposed to merely internalising). To this end, the vitamin B<ce:inf loc="post">12</ce:inf> absorption pathway has been relatively well investigated for its potential to ‘carry’ therapeutic biomolecules, as well as nanoparticles as drug carriers, transepithelially. However, these studies have been mainly conducted in Caco-2 cells, as an <ce:italic>in vitro</ce:italic> model of the intestinal epithelium, which is an obvious selection based on physiological absorption of dietary B<ce:inf loc="post">12</ce:inf>.</ce:para><ce:para id="p0235" view="all">Information on the presence of the transcytotic machinery involved in transepithelial trafficking of B<ce:inf loc="post">12</ce:inf> in the bronchial epithelium is, to our knowledge, not available, although the expression of cubilin in alveolar A549 cell line has recently been reported <ce:cross-ref refid="bb0095" id="cf0265">[19]</ce:cross-ref>. Therefore, a combination of molecular biology and immunostaining techniques was used to determine the presence of the relevant components at mRNA and protein level in airway Calu-3 cells. mRNA expression of cubilin and TCII receptor was analysed using PCR and gel electrophoresis. The data demonstrated the expression of both components (<ce:cross-ref refid="f0010" id="cf0270">Fig. 1</ce:cross-ref>) in Calu-3 cells, as in Caco-2 cells, which were used as a control as the expression of cubilin and TCII receptor in these cells is widely acknowledged <ce:cross-refs refid="bb0155 bb0160 bb0165" id="cf0275">[31–33]</ce:cross-refs>. The expression of cubilin, TCII receptor and TCII protein in Calu-3 cells was also confirmed at protein level using immunofluorescence (<ce:cross-ref refid="f0010" id="cf0280">Fig. 1</ce:cross-ref>b). The expression of these constituents of the B<ce:inf loc="post">12</ce:inf> transport system at gene and protein level therefore indicates that vitamin B<ce:inf loc="post">12</ce:inf> cell trafficking activity may operate in the airway epithelium.</ce:para><ce:para id="p0240" view="all">Cubilin has been previously shown to be expressed in the renal proximal tubule and the visceral yolk sac <ce:cross-ref refid="bb0170" id="cf0285">[34]</ce:cross-ref>, the placental cytotrophoblast and possibly other tissues such as thymus <ce:cross-ref refid="bb0175" id="cf0290">[35]</ce:cross-ref>, in addition to the small intestinal epithelium. Whilst its expression in the renal proximal tubule, which exhibits a very extensive apical endocytic apparatus involved in the re-absorption and conservation of important molecules (such as vitamin B<ce:inf loc="post">12</ce:inf>) filtered in the glomeruli, is perhaps unsurprising, cubilin functionality in the airway epithelial cells is unclear. However, it presumably plays a physiological role in the uptake (rather than transepithelial transport) of B<ce:inf loc="post">12</ce:inf> as an essential agent in key metabolic processes, similarly to the expression of folate receptor (another vitamin B subtype) in airway epithelial cells <ce:cross-ref refid="bb0105" id="cf0295">[21]</ce:cross-ref>.</ce:para><ce:para id="p0245" view="all">Following the demonstration that Calu-3 cells express vitamin B<ce:inf loc="post">12</ce:inf> receptor, TCII receptor and TCII protein, we next determined the presence of other structural cell components participating in the process of endocytosis or transcytosis. This was deemed necessary as whilst the expression of cubilin and TCII receptor is required for the ligand–receptor binding stage of endocytosis, other components of the cell machinery are responsible for subsequent trafficking of B<ce:inf loc="post">12</ce:inf>. Further work therefore determined whether Calu-3 cells express relevant key proteins involved in two specific endocytic pathways, including the essential components of clathrin-coated pits, implicated in the internalisation of the soluble B<ce:inf loc="post">12</ce:inf>-IF complex, as well as caveolae (caveolin-1) as another route for material internalisation. The work confirmed the expression of these proteins by airway Calu-3 cells (<ce:cross-ref refid="f0020" id="cf0300">Fig. 3</ce:cross-ref>), which was also shown in a previous study <ce:cross-ref refid="bb0130" id="cf0305">[26]</ce:cross-ref>.</ce:para><ce:para id="p0250" view="all">Amino derivatization of B<ce:inf loc="post">12</ce:inf> and characterization of B<ce:inf loc="post">12</ce:inf>-bearing nanoparticles in terms of surface modification, size and charge, were reported in our recent work <ce:cross-ref refid="bb0090" id="cf0310">[18]</ce:cross-ref>. These nanoparticles, used as model therapeutic nanocarriers or nanomedicines, demonstrated interesting cell uptake and transport behaviours. B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles of 50<ce:hsp sp="0.25"/>nm and 100<ce:hsp sp="0.25"/>nm (nominal diameter) demonstrated improved cell uptake and transport across the cell layers, as compared to unmodified nanoparticles, with IF modestly influencing the extent of cell uptake (<ce:cross-ref refid="f0015" id="cf0315">Fig. 2</ce:cross-ref>). Fluorescently-labelled B<ce:inf loc="post">12</ce:inf>-decorated nanoparticles were also clearly observed within Calu-3 cells following imaging by confocal microscopy (Supporting information, Fig. S3). In addition to demonstrating higher cell uptake, B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles transported across the cell layers notably more efficiently than unmodified nanoparticles, irrespective of their size. In the absence of IF, nanoparticle transport was somewhat reduced, indicating that IF plays a role (albeit minor) in the trafficking of B<ce:inf loc="post">12</ce:inf>-bearing nanoparticles. It is interesting to note that the transport of 100<ce:hsp sp="0.25"/>nm nanoparticles was significantly larger relative to 50<ce:hsp sp="0.25"/>nm nanoparticle, despite 50<ce:hsp sp="0.25"/>nm B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles being internalised by the cells to a greater extent.</ce:para><ce:para id="p0255" view="all"><ce:italic>In vivo</ce:italic>, native soluble B<ce:inf loc="post">12</ce:inf> binds to IF and the B<ce:inf loc="post">12</ce:inf>-IF complex in turn binds to the cubilin receptor situated in the apical brush border membrane of the ileal mucosa <ce:cross-ref refid="bb0180" id="cf0320">[36]</ce:cross-ref>. Association of cubilin with megalin, a member of the LDL receptor-related family of endocytic receptors, <ce:cross-refs refid="bb0185 bb0190" id="cf0325">[37,38]</ce:cross-refs> leads to internalisation of the entire cubilin-IF-B<ce:inf loc="post">12</ce:inf> complex <ce:italic>via</ce:italic> clathrin-coated vesicles <ce:cross-ref refid="bb0195" id="cf0330">[39]</ce:cross-ref>. Our recent work showed that in intestinal Caco-2 cells soluble vitamin B<ce:inf loc="post">12</ce:inf> internalises <ce:italic>via</ce:italic> clathrin-mediated endocytosis <ce:cross-ref refid="bb0090" id="cf0335">[18]</ce:cross-ref>. The mechanism of cell entry of soluble B<ce:inf loc="post">12</ce:inf> in airway Calu-3 cells was also probed with chlorpromazine and filipin as cell trafficking inhibitors of clathrin- and caveolae-mediated endocytosis, respectively <ce:cross-refs refid="bb0115 bb0145 bb0150" id="cf0340">[23,29,30]</ce:cross-refs>. Soluble B<ce:inf loc="post">12</ce:inf> internalisation and transport were significantly suppressed by the action of chlorpromazine. The caveolae inhibitor, filipin, displayed a modest effect on these phenomena (<ce:cross-ref refid="f0025" id="cf0345">Fig. 4</ce:cross-ref>), with a 25% reduction in uptake and some influence in the pattern of transport over the three-hour experiment. The data therefore suggests that vitamin B<ce:inf loc="post">12</ce:inf> is trafficked predominantly <ce:italic>via</ce:italic> a clathrin-mediated route in airway Calu-3 cells, which is in accord with previous reports related to other epithelial tissue <ce:cross-refs refid="bb0200 bb0205" id="cf0350">[40,41]</ce:cross-refs>, as well as our observations with intestinal Caco-2 cells <ce:cross-ref refid="bb0090" id="cf0355">[18]</ce:cross-ref>. However, whilst in intestinal Caco-2 cells caveolae played no role in the internalisation of soluble B<ce:inf loc="post">12</ce:inf>, the data suggests that, to a degree, there might be an element of cross-talk between the two pathways in airway Calu-3 cells. Furthermore, paracellular transport of soluble vitamin B<ce:inf loc="post">12</ce:inf> cannot be ruled out, as suggested for other vitamin B family sub-types <ce:cross-ref refid="bb0210" id="cf0360">[42]</ce:cross-ref>, which may partly contribute to the observed high level of permeability across the epithelial cells. Similar levels of transepithelial transport have also been reported in intestinal Caco-2 monolayers in studies using comparative (higher than physiological) doses of vitamin B<ce:inf loc="post">12</ce:inf> <ce:cross-refs refid="bb0215 bb0220" id="cf0365">[43,44]</ce:cross-refs>.</ce:para><ce:para id="p0260" view="all">The cell internalisation route of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles was probed by the same endocytosis inhibitors used in experiments establishing soluble B<ce:inf loc="post">12</ce:inf> trafficking. The data shows that cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-bearing nanoparticles was inhibited by both chlorpromazine and filipin (<ce:cross-ref refid="f0030" id="cf0370">Fig. 5</ce:cross-ref>), implying that these nanoparticles are trafficked by both clathrin-mediated and caveolae-mediated pathways. Interestingly, this finding is notably different to the trends observed for Caco-2 cells, where transport of 50<ce:hsp sp="0.25"/>nm B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles takes place by a route that predominantly involves caveolae <ce:cross-ref refid="bb0090" id="cf0375">[18]</ce:cross-ref>. This work therefore not only identifies the presence of biological machinery of vitamin B<ce:inf loc="post">12</ce:inf> trafficking in airway epithelial cells but also demonstrates B<ce:inf loc="post">12</ce:inf>-mediated nanoparticle transport into and across the airway epithelium cells — a previously unreported observation. The trafficking of B<ce:inf loc="post">12</ce:inf> bioconjugated nanoparticles in the Calu-3 airway model occurs through different endocytic pathways compared to both soluble B<ce:inf loc="post">12</ce:inf> and unmodified nanoparticles. Demonstration that cell uptake and systemic entry of nano-sized model drug carriers can occur through the airway epithelium <ce:italic>via</ce:italic> the vitamin B<ce:inf loc="post">12</ce:inf> transport system is of potential significant impact in the field of nanomedicine and warrants further research. However, it must be noted that our study was based on a single cell line. The findings will of course have to be confirmed in the future using other airway cell types and, importantly, <ce:italic>in vivo</ce:italic>.</ce:para><ce:para id="p0265" view="all">A potential limitation to nanocarrier delivery across the airway mucosa is the presence of mucus. The viscoelastic and adhesive mucus layer that lines the bronchial epithelium presents a barrier to transmucosal movement of nanoparticles and this should be considered when designing nanocarrier delivery systems for systemic delivery through the airways. Particle mobility in mucus is dependent on their surface properties, whereby anionic particles diffuse more efficiently (up to 20–30 times faster) than cationic particles <ce:cross-ref refid="bb0225" id="cf0380">[45]</ce:cross-ref> and surface PEGylation remarkably enhances nanoparticle movement in mucus <ce:cross-refs refid="bb0230 bb0235" id="cf0385">[46,47]</ce:cross-refs>. Whilst our work shows the expression, functionality and nanoparticle transport capacity of the vitamin B<ce:inf loc="post">12</ce:inf> pathway in a bronchial epithelial cell line, interestingly, cubilin expression has also recently been demonstrated in human alveolar A549 cells <ce:cross-ref refid="bb0095" id="cf0390">[19]</ce:cross-ref>. Assuming that this biological transport pathway is also functional in the alveolar epithelium, it is possible that the deep lung region also contributes to the absorption of B<ce:inf loc="post">12</ce:inf> decorated nanocarriers, which is an interesting prospect considering the enormous surface area of the alveolar epithelium and the lack of mucus barrier in this region. This may be examined in the future <ce:italic>in vitro</ce:italic> using primary human alveolar epithelial cells <ce:cross-refs refid="bb0240 bb0245" id="cf0395">[48,49]</ce:cross-refs>, or in animal studies.</ce:para></ce:section><ce:section id="s0025" view="all"><ce:label>5</ce:label><ce:section-title id="st0040">Conclusion</ce:section-title><ce:para id="p0270" view="all">The work investigated the presence of the vitamin B<ce:inf loc="post">12</ce:inf> transport system and its capacity to transport nanoparticles in polarised airway Calu-3 cells. The expression of B<ce:inf loc="post">12</ce:inf> transcytosis component proteins in Calu-3 cells was shown at mRNA and protein level. B<ce:inf loc="post">12</ce:inf>-decorated nanoparticles displayed a larger capacity to enter and transport across airway epithelial cell layers (with or without the presence of IF) compared to unmodified nanoparticles. Whilst soluble B<ce:inf loc="post">12</ce:inf> was found to internalise into Calu-3 cells predominantly by a clathrin-mediated route, cell uptake and transport of B<ce:inf loc="post">12</ce:inf>-conjugated nanoparticles were dramatically affected by both clathrin and caveolae inhibition, suggesting a different B<ce:inf loc="post">12</ce:inf> intracellular trafficking as a result of its mobilization on nanoparticle surface. The work therefore reveals a previously unexplored route of nanoparticle cell entry and transepithelial transport across the airway epithelium, with a potentially important impact in the area of mucosal delivery of nanomedicines.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac1000" view="all"><ce:section-title id="st2160">Acknowledgements</ce:section-title><ce:para id="p2000" view="all">This work was funded by a <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">BBSRC Industrial CASE</ce:grant-sponsor> grant with <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">UCB Pharma</ce:grant-sponsor>. The authors would like to thank Dr Francisco Fernández Trillo for his assistance with nanoparticle characterisation.</ce:para></ce:acknowledgment><ce:appendices view="all"><ce:section id="s0140" view="extended"><ce:label>Appendix A</ce:label><ce:section-title id="st0160">Supplementary</ce:section-title><ce:para id="p0275" view="all"><ce:display><ce:e-component id="ec0005"><ce:caption id="ca0030"><ce:simple-para id="sp0040" view="all">Supplementary figures.</ce:simple-para></ce:caption><ce:link locator="mmc1"/></ce:e-component></ce:display></ce:para></ce:section><ce:section view="compact-standard" id="s0145"><ce:label>Appendix A</ce:label><ce:section-title id="st0165">Supplementary data</ce:section-title><ce:para id="p0280" view="all">Modification of nanoparticles with B<ce:inf loc="post">12</ce:inf> (shown by fluorescence characterization), the influence of nanoparticles on cell layer TEER, cell uptake of nanoparticles and the effect of chemical inhibitors on cell uptake of pathway selective ligands in airway Calu-3 layers are shown as supplementary material. Supplementary data to this article can be found online at <ce:inter-ref xlink:href="doi:10.1016/j.jconrel.2013.08.028" id="ir0035" xlink:type="simple">http://dx.doi.org/10.1016/j.jconrel.2013.08.028</ce:inter-ref>.</ce:para></ce:section></ce:appendices></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0045">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Thanou</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Verhoef</ce:surname></sb:author><sb:author><ce:given-name>H.E.</ce:given-name><ce:surname>Junginger</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Oral drug absorption enhancement by chitosan and its derivatives</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Drug Deliv. Rev.</sb:maintitle></sb:title><sb:volume-nr>52</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>117</sb:first-page><sb:last-page>126</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Vllasaliu</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Casettari</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Fowler</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Exposito-Harris</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Garnett</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Illum</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Stolnik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Absorption-promoting effects of chitosan in airway and intestinal cell lines: a comparative study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>430</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>151</sb:first-page><sb:last-page>160</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.N.</ce:given-name><ce:surname>Salama</ce:surname></sb:author><sb:author><ce:given-name>N.D.</ce:given-name><ce:surname>Eddington</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Fasano</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tight junction modulation and its relationship to drug delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Drug Deliv. Rev.</sb:maintitle></sb:title><sb:volume-nr>58</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>15</sb:first-page><sb:last-page>28</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Vllasaliu</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Fowler</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Garnett</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Eaton</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Stolnik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: a comparison</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle></sb:title><sb:volume-nr>415</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>579</sb:first-page><sb:last-page>585</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author><sb:author><ce:given-name>S.W.</ce:given-name><ce:surname>Westwood</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Habberfield</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Bioconjug. Chem.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>459</sb:first-page><sb:last-page>465</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Tuma</ce:surname></sb:author><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Hubbard</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transcytosis: crossing cellular barriers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Physiol. Rev.</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>871</sb:first-page><sb:last-page>932</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Arthur</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Walker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Vitamin B12-mediated transport of nanoparticles across Caco-2 cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>179</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>247</sb:first-page><sb:last-page>255</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Vllasaliu</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Alexander</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Garnett</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Eaton</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Stolnik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Fc-mediated transport of nanoparticles across airway epithelial cell layers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>158</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>479</sb:first-page><sb:last-page>486</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Oral Delivery of Therapeutic Proteins and Peptides by the Vitamin B12 Uptake System</sb:maintitle></sb:title></sb:contribution><sb:host><sb:book><sb:date>1995</sb:date><sb:publisher><sb:name>ACS</sb:name><sb:location>Washington DC</sb:location></sb:publisher></sb:book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><ce:other-ref id="or0015"><ce:textref id="tr0005">K.B. Chalasani, P.V. Diwan, K.P. Raghavan, S.K. Jain, K.K. Rao, G.J. Russell-Jones, Vitamin B12-biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines, in, US patent, 2002.</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.B.</ce:given-name><ce:surname>Chalasani</ce:surname></sb:author><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author><sb:author><ce:given-name>A.K.</ce:given-name><ce:surname>Jain</ce:surname></sb:author><sb:author><ce:given-name>P.V.</ce:given-name><ce:surname>Diwan</ce:surname></sb:author><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Jain</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>122</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>141</sb:first-page><sb:last-page>150</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Drug Target.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>113</sb:first-page><sb:last-page>123</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Dix</ce:surname></sb:author><sb:author><ce:given-name>I.F.</ce:given-name><ce:surname>Hassan</ce:surname></sb:author><sb:author><ce:given-name>H.Y.</ce:given-name><ce:surname>Obray</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Shah</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Wilson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The transport of vitamin B12 through polarized monolayers of Caco-2 cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gastroenterology</sb:maintitle></sb:title><sb:volume-nr>98</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>1272</sb:first-page><sb:last-page>1279</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Ramanujam</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ramasamy</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Expression of cobalamin transport proteins and cobalamin transcytosis by colon adenocarcinoma cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Physiol.</sb:maintitle></sb:title><sb:volume-nr>260</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>G416</sb:first-page><sb:last-page>G422</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Schohn</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Gueant</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Girr</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Nexo</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Baricault</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Zweibaum</ce:surname></sb:author><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Nicolas</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Synthesis and secretion of a cobalamin-binding protein by HT 29 cell line</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. J.</sb:maintitle></sb:title><sb:volume-nr>280</sb:volume-nr></sb:series><sb:issue-nr>Pt 2</sb:issue-nr><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>427</sb:first-page><sb:last-page>430</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Gueant</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Masson</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Schohn</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Girr</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Saunier</ce:surname></sb:author><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Nicolas</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Receptor-mediated endocytosis of the intrinsic factor-cobalamin complex in HT 29, a human colon carcinoma cell line</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>FEBS Lett.</sb:maintitle></sb:title><sb:volume-nr>297</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>229</sb:first-page><sb:last-page>232</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.B.</ce:given-name><ce:surname>Chalasani</ce:surname></sb:author><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Russell-Jones</ce:surname></sb:author><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Yandrapu</ce:surname></sb:author><sb:author><ce:given-name>P.V.</ce:given-name><ce:surname>Diwan</ce:surname></sb:author><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Jain</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>117</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>421</sb:first-page><sb:last-page>429</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Fowler</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Vllasaliu</ce:surname></sb:author><sb:author><ce:given-name>F.F.</ce:given-name><ce:surname>Trillo</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Garnett</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Alexander</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Horsley</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Whitcombe</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Eaton</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Stolnik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nanoparticle transport in epithelial cells: pathway switching through bioconjugation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Small</sb:maintitle></sb:title></sb:series><sb:date>2013</sb:date></sb:issue><ce:doi>10.1002/smll.201202623</ce:doi></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Vortherms</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Kahkoska</ce:surname></sb:author><sb:author><ce:given-name>A.E.</ce:given-name><ce:surname>Rabideau</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Zubieta</ce:surname></sb:author><sb:author><ce:given-name>L.L.</ce:given-name><ce:surname>Andersen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Madsen</ce:surname></sb:author><sb:author><ce:given-name>R.P.</ce:given-name><ce:surname>Doyle</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A water soluble vitamin B12-ReI fluorescent conjugate for cell uptake screens: use in the confirmation of cubilin in the lung cancer line A549</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Chem. Commun.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>9792</sb:first-page><sb:last-page>9794</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><ce:other-ref id="or0020"><ce:textref id="tr0010">A.O. Saeed, J.P. Magnusson, E. Moradi, M. Soliman, W. Wang, S. Stolnik, K.J. Thurecht, S.M. Howdle, C. Alexander, Modular construction of multifunctional bioresponsive cell-targeted nanoparticles for gene delivery, Bioconjug. Chem. 22 156–168.</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Moradi</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Vllasaliu</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Garnett</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Falcone</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Stolnik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ligand density and clustering effects on endocytosis of folate modified nanoparticles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>RSC Adv.</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>3025</sb:first-page><sb:last-page>3033</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Sambrook</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Russell</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Molecular Cloning: A Laboratory Manual</sb:maintitle></sb:title></sb:contribution><sb:host><sb:book><sb:edition>3rd ed.</sb:edition><sb:date>2001</sb:date><sb:publisher><sb:name>Cold Spring Harbor Laboratory Press</sb:name></sb:publisher></sb:book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Rejman</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Oberle</ce:surname></sb:author><sb:author><ce:given-name>I.S.</ce:given-name><ce:surname>Zuhorn</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hoekstra</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. J.</sb:maintitle></sb:title><sb:volume-nr>377</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>159</sb:first-page><sb:last-page>169</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Zhu</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Wu</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Hydroxypropyl-beta-cyclodextrin enhanced determination for the Vitamin B12 by fluorescence quenching method</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Fluoresc.</sb:maintitle></sb:title><sb:volume-nr>17</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>265</sb:first-page><sb:last-page>270</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Zhao</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Lu</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Tang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Fluorescence resonance energy transfer between acridine orange and rhodamine 6G and its analytical application for vitamin B12 with flow-injection laser-induced fluorescence detection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Talanta</sb:maintitle></sb:title><sb:volume-nr>77</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>176</sb:first-page><sb:last-page>181</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.A.</ce:given-name><ce:surname>Bradbury</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Clark</ce:surname></sb:author><sb:author><ce:given-name>S.C.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>C.C.</ce:given-name><ce:surname>Widnell</ce:surname></sb:author><sb:author><ce:given-name>H.S.t.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Bridges</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Characterization of the internalization pathways for the cystic fibrosis transmembrane conductance regulator</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Physiol.</sb:maintitle></sb:title><sb:volume-nr>276</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>L659</sb:first-page><sb:last-page>L668</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Motley</ce:surname></sb:author><sb:author><ce:given-name>N.A.</ce:given-name><ce:surname>Bright</ce:surname></sb:author><sb:author><ce:given-name>M.N.</ce:given-name><ce:surname>Seaman</ce:surname></sb:author><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Robinson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Clathrin-mediated endocytosis in AP-2-depleted cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>162</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>909</sb:first-page><sb:last-page>918</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Lakadamyali</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Rust</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Zhuang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>124</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>997</sb:first-page><sb:last-page>1009</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Orlandi</ce:surname></sb:author><sb:author><ce:given-name>P.H.</ce:given-name><ce:surname>Fishman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>141</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>905</sb:first-page><sb:last-page>915</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.E.</ce:given-name><ce:surname>Schnitzer</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Oh</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Pinney</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Allard</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>127</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>1217</sb:first-page><sb:last-page>1232</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Pons</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Guy</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Lambert</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Hatier</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gueant</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transcytosis and coenzymatic conversion of [(57)Co]cobalamin bound to either endogenous transcobalamin II or exogenous intrinsic factor in caco-2 cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell. Physiol. Biochem.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>135</sb:first-page><sb:last-page>148</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Bose</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Effect of disulfide bonds of transcobalamin II receptor on its activity and basolateral targeting in human intestinal epithelial Caco-2 cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>272</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>20920</sb:first-page><sb:last-page>20928</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>[33]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Bose</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author><sb:author><ce:given-name>N.M.</ce:given-name><ce:surname>Dahms</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Bipolar functional expression of transcobalamin II receptor in human intestinal epithelial Caco-2 cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>272</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>3538</sb:first-page><sb:last-page>3543</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>[34]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Sahali</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Mulliez</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Chatelet</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Laurent-Winter</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Citadelle</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Roux</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Ronco</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Verroust</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Coexpression in humans by kidney and fetal envelopes of a 280<ce:hsp sp="0.25"/>kDa-coated pit-restricted protein. Similarity with the murine target of teratogenic antibodies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>140</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>33</sb:first-page><sb:last-page>44</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>[35]</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Hammad</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Barth</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Knaak</ce:surname></sb:author><sb:author><ce:given-name>W.S.</ce:given-name><ce:surname>Argraves</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>275</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>12003</sb:first-page><sb:last-page>12008</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>[36]</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Seetharam</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Alpers</ce:surname></sb:author><sb:author><ce:given-name>R.H.</ce:given-name><ce:surname>Allen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Isolation and characterization of the ileal receptor for intrinsic factor-cobalamin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>256</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>3785</sb:first-page><sb:last-page>3790</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>[37]</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gliemann</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>379</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>951</sb:first-page><sb:last-page>964</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>[38]</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.E.</ce:given-name><ce:surname>Willnow</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Mol. Med.</sb:maintitle></sb:title><sb:volume-nr>77</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>306</sb:first-page><sb:last-page>315</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>[39]</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.A.</ce:given-name><ce:surname>Pedersen</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Chakraborty</ce:surname></sb:author><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Steinhauser</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Traub</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Madsen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>AMN directs endocytosis of the intrinsic factor-vitamin B(12) receptor cubam by engaging ARH or Dab2</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Traffic</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>706</sb:first-page><sb:last-page>720</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>[40]</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Moestrup</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Birn</ce:surname></sb:author><sb:author><ce:given-name>P.B.</ce:given-name><ce:surname>Fischer</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Petersen</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Verroust</ce:surname></sb:author><sb:author><ce:given-name>R.B.</ce:given-name><ce:surname>Sim</ce:surname></sb:author><sb:author><ce:given-name>E.I.</ce:given-name><ce:surname>Christensen</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Nexo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>93</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>8612</sb:first-page><sb:last-page>8617</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>[41]</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.I.</ce:given-name><ce:surname>Christensen</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Birn</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Megalin and cubilin: multifunctional endocytic receptors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>256</sb:first-page><sb:last-page>266</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>[42]</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Zielinska-Dawidziak</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Grajek</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Olejnik</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Czaczyk</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Grajek</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transport of high concentration of thiamin, riboflavin and pyridoxine across intestinal epithelial cells Caco-2</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Nutr. Sci. Vitaminol.</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>423</sb:first-page><sb:last-page>429</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>[43]</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Sarti</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Iqbal</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Muller</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Shahnaz</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Rahmat</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bernkop-Schnurch</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Poly(acrylic acid)-cysteine for oral vitamin B12 delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Anal. Biochem.</sb:maintitle></sb:title><sb:volume-nr>420</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>13</sb:first-page><sb:last-page>19</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>[44]</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Tronde</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Norden</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Marchner</ce:surname></sb:author><sb:author><ce:given-name>A.K.</ce:given-name><ce:surname>Wendel</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Lennernas</ce:surname></sb:author><sb:author><ce:given-name>U.H.</ce:given-name><ce:surname>Bengtsson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Pulmonary absorption rate and bioavailability of drugs <ce:italic>in vivo</ce:italic> in rats: structure–absorption relationships and physicochemical profiling of inhaled drugs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pharm. Sci.</sb:maintitle></sb:title><sb:volume-nr>92</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>1216</sb:first-page><sb:last-page>1233</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>[45]</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Crater</ce:surname></sb:author><sb:author><ce:given-name>R.L.</ce:given-name><ce:surname>Carrier</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Barrier properties of gastrointestinal mucus to nanoparticle transport</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Macromol. Biosci.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>1473</sb:first-page><sb:last-page>1483</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>[46]</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Lai</ce:surname></sb:author><sb:author><ce:given-name>D.E.</ce:given-name><ce:surname>O'Hanlon</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Harrold</ce:surname></sb:author><sb:author><ce:given-name>S.T.</ce:given-name><ce:surname>Man</ce:surname></sb:author><sb:author><ce:given-name>Y.Y.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Cone</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Hanes</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>104</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1482</sb:first-page><sb:last-page>1487</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>[47]</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Cu</ce:surname></sb:author><sb:author><ce:given-name>W.M.</ce:given-name><ce:surname>Saltzman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharm.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>173</sb:first-page><sb:last-page>181</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>[48]</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.J.</ce:given-name><ce:surname>Elbert</ce:surname></sb:author><sb:author><ce:given-name>U.F.</ce:given-name><ce:surname>Schafer</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Schafers</ce:surname></sb:author><sb:author><ce:given-name>K.J.</ce:given-name><ce:surname>Kim</ce:surname></sb:author><sb:author><ce:given-name>V.H.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Lehr</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>601</sb:first-page><sb:last-page>608</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>[49]</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Daum</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kuehn</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Hein</ce:surname></sb:author><sb:author><ce:given-name>U.F.</ce:given-name><ce:surname>Schaefer</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Huwer</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Lehr</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Isolation, cultivation, and application of human alveolar epithelial cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>R.R.</ce:given-name><ce:surname>Mitry</ce:surname></sb:editor><sb:editor><ce:given-name>R.D.</ce:given-name><ce:surname>Hughes</ce:surname></sb:editor></sb:editors><sb:title><sb:maintitle>Human Cell Culture Protocols</sb:maintitle></sb:title><sb:date>2011</sb:date><sb:publisher><sb:name>Humana Press</sb:name><sb:location>New Jersey</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>31</sb:first-page><sb:last-page>42</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>